semaglutide news october 20 2025 FDA Approves Oral as First GLP-1 Pill for Weight Loss Proteomic changes upon treatment with

Wadden TA et al

As the TRIUMPH Phase 3 trials progress through 2026 and beyond, the full picture of retatrutides efficacy and safety profile will come into sharper focus

But theres no evidence that this causes substantial weight loss. The gastrointestinal side effects of GLP-1 agonists are well documented, and GLP-1 boosting supplements draw consumers in by bragging about their lack of side effects

Uncontrolled hypertension (defined as systolic blood pressure above 140 mm Hg or diastolic blood pressure above 90 mm Hg, despite concurrent treatment with 2 antihypertensive medications)

Blood pressure medications may also need adjustment downward as semaglutide's metabolic effects lower cardiovascular strain

Subgroups that hit both lost a fraction of the lean mass of those who hit neither